CMS: Medicaid DSH payments will consider what Medicare, third-party pay

In a final rule issued on March 30, CMS clarified uncompensated care costs for Medicaid patients are limited by what a hospital received from other sources, such as commercial insurers, Medicare or the patients themselves.

This interpretation of the rules surrounding Medicaid disproportionate share hospital (DSH) payments had already existed, but the new regulation makes it explicit.

The new rule only slightly modifies the text of the regulation to spell out that for purposes of calculating hospital-specific DSH limits, “costs” means the costs net of third-party payments received.

“For example, if a hospital treats two Medicaid eligible patients at a cost of $2,000 and receives a $500 payment from a third party for each individual and a $100 payment from Medicaid for each individual, the total uncompensated care cost to the hospital is $800, regardless of whether the payments received for one patient exceeded the cost of providing the service to that individual,” the rule said.

CMS said this had been a source of confusion prior to a 2008 DSH rule, with some hospitals and states excluding uncompensated care costs and payments related to Medicaid-eligible patients who had some sort of third-party coverage. Other facilities excluded only the payments, leading to “an artificial inflation of uncompensated care costs and, correspondingly, of hospital-specific DSH limits.” This allowed some hospitals to be paid twice for the same costs—once by Medicaid and again by a third-party payer or Medicare.

Many commenters on the proposed rule claimed the new language violated the existing laws on DSH payments. CMS argued the change betters support the intent of the original statute, ensuring Medicaid DSH payments don’t go to services which have already been compensated. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.